Real life experience of guselkumab in patients with psoriasis ניסיון בתנאי אמת של טיפול בגוזלקומאב בחולי פסוריאזיס

Background: High levels of efficacy were demonstrated in randomized controlled trials assessing the efficacy of guselkumab, however real-life data is lacking.

Objective: To assess efficacy and safety of guselkumab in a cohort of psoriasis patients heavily pretreated with biologic agents in a real-life setting.

Methods: Retrospective cohort study of patients with moderate-severe psoriasis treated with guselkumab. Primary efficacy endpoint was percent patients achieving PASI >90 at week 24.

Results: The cohort included 28 patients of mean age 60±13 years. Mean baseline PASI was 26 ± 11. Guselkumab was initiated after mean of 4.0±0.9 prior biologics failed over mean period of 7.6±3.8 years. Mean duration of treatment was 6.7±2.5 months; of 24 patients completing minimum 24 weeks of treatment, 19 (79%) patients achieved PASI ≥ 75 response, 16 (67%) ≥ 90 response, 4 (17%) 100 response; with 5 (21%) non-responders (< PASI 50). No adverse effects were found.

Conclusions: This study confirms the efficacy and safety of guselkumab in real-world clinical practice, although for a lesser degree compared with clinical trials.